Patents by Inventor Vincent Jacques

Vincent Jacques has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY USING ENANTIOPURE, OXY-SUBSTITUTED, DEUTERIUM-ENRICHED 5-(BENZYL)-5-DEUTERO-THIAZOLIDINE-2,4-DIONES FOR TREATMENT OF MEDICAL DISORDERS
    Publication number: 20200390753
    Abstract: The invention provides combination therapy using enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating nonalcoholic steatohepatitis, diabetes, fibrotic disorders, and other disorders using the combination therapy.
    Type: Application
    Filed: December 11, 2019
    Publication date: December 17, 2020
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
  • 5-DEUTERO-THIAZOLIDINE-2,4-DIONE COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME
    Publication number: 20200253937
    Abstract: The invention provides deuterium-enriched thiazolidine-2,4-dione compounds (i.e., deuterium-enriched glitazone compounds), enantiopure forms of deuterium-enriched glitazone compounds, pharmaceutical compositions, and methods of treating medical disorders, such as a metabolic disorder, neurological disorder, cancer, or other disorder using deuterium-enriched glitazone compounds, which are preferably in enantiopure form.
    Type: Application
    Filed: August 15, 2019
    Publication date: August 13, 2020
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
  • 5-DEUTERO-THIAZOLIDINYLDIONE COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME
    Publication number: 20200239457
    Abstract: The invention provides deuterium-enriched thiazolidine-2,4-dione compounds (i.e., deuterium-enriched glitazone compounds), enantiopure forms of deuterium-enriched glitazone compounds, pharmaceutical compositions, and methods of treating medical disorders, such as a metabolic disorder, neurological disorders, cancer, or other disorder using deuterium-enriched glitazone compounds, which may be in enantiopure form.
    Type: Application
    Filed: September 11, 2019
    Publication date: July 30, 2020
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
  • HISTONE DEACETYLASE INHIBITORS
    Publication number: 20200148704
    Abstract: This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
    Type: Application
    Filed: November 8, 2019
    Publication date: May 14, 2020
    Inventors: Vincent Jacques, James R. Rusche, Norton P. Peet, Jasbir Singh
  • Histone deacetylase inhibitors
    Patent number: 10526346
    Abstract: This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: January 7, 2020
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Vincent Jacques, James R. Rusche, Norton P. Peet, Jasbir Singh
  • 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME
    Publication number: 20200000788
    Abstract: The invention provides 5-deuterium-enriched 2,4-thiazolidinediones (e.g., 5-[4-[2-(5-ethyl-2-pyridyl)-2-oxoethoxy]benzyl]-5-deutero-thiazolidine-2,4-dione), deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.
    Type: Application
    Filed: March 5, 2019
    Publication date: January 2, 2020
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
  • HDAC INHIBITORS
    Publication number: 20190382351
    Abstract: Disclosed herein are compounds of formula (I), and methods of inhibiting histone deacetylase (“HDAC”) enzymes (e.g.
    Type: Application
    Filed: August 22, 2019
    Publication date: December 19, 2019
    Inventors: Vincent Jacques, James R. Rusche
  • MICROCATHETER OCCLUSION EMBOLIZATION CATHETER
    Publication number: 20190298389
    Abstract: Devices used to deliver a substance within a patient's body are disclosed. The devices may include a microcatheter configured to deliver the substance to a targeted site. The microcatheter may include an expandable member to temporarily restrict blood flow in a vessel, a flow restriction member to restrict flow of material out a distal end of the microcatheter, and a port disposed proximal of the expandable member.
    Type: Application
    Filed: March 27, 2019
    Publication date: October 3, 2019
    Inventors: Michael Hallisey, Tony Vincent Jacques, Jeffrey P. Radziunas
  • HDAC inhibitors
    Patent number: 10428028
    Abstract: Disclosed herein are compounds of formula (I), and methods of inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3) using compounds of formula (I).
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: October 1, 2019
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Vincent Jacques, James R. Rusche
  • METHODS OF TREATING NEUROLOGICAL, METABOLIC, AND OTHER DISORDERS USING ENANTIOPURE DEUTERIUM-ENRICHED PIOGLITAZONE
    Publication number: 20190269665
    Abstract: The invention provides enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating neurological disorders, cancer, respiratory disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched pioglitazone. A preferred aspect of the invention provides methods of treating Alzheimer's disease, non-small cell lung cancer, hepatocellular carcinoma, and chronic obstructive pulmonary disease using enantiopure deuterium-enriched pioglitazone.
    Type: Application
    Filed: December 6, 2018
    Publication date: September 5, 2019
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
  • HISTONE DEACETYLASE INHIBITORS
    Publication number: 20190233439
    Abstract: This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
    Type: Application
    Filed: March 12, 2019
    Publication date: August 1, 2019
    Inventors: Vincent Jacques, James R. Rusche, Norton P. Peet, Jasbir Singh
  • Histone deacetylase inhibitors
    Patent number: 10301323
    Abstract: This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: May 28, 2019
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Vincent Jacques, James R. Rusche, Norton P. Peet, Jasbir Singh
  • Histone deacetylase inhibitors
    Patent number: 10280182
    Abstract: This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: May 7, 2019
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Vincent Jacques, James R. Rusche, Norton P. Peet, Jasbir Singh
  • 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
    Patent number: 10265305
    Abstract: The invention provides 5-deuterium-enriched 2,4-thiazolidinediones (e.g., 5-[4-[2-(5-ethyl-2-pyridyl)-2-oxoethoxy]benzyl]-5-deutero-thiazolidine-2,4-dione), deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: April 23, 2019
    Assignee: Poxel SA
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
  • Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
    Patent number: 10188639
    Abstract: The invention provides enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating neurological disorders, cancer, respiratory disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched pioglitazone. A preferred aspect of the invention provides methods of treating Alzheimer's disease, non-small cell lung cancer, hepatocellular carcinoma, and chronic obstructive pulmonary disease using enantiopure deuterium-enriched pioglitazone.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: January 29, 2019
    Assignee: DeuteRx, LLC
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus H. T. van der Ploeg
  • Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
    Patent number: 10189858
    Abstract: The invention provides deuterium-enriched isoindolinonyl-piperidinonyl conjugates, deuterium-enriched oxoquinazolin-3(4H)-yl-piperidinonyl conjugates, pharmaceutical compositions, and methods of using such conjugates and pharmaceutical compositions to treat cancer, angiogenesis disorders, immune disorders, and other medical disorders.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: January 29, 2019
    Assignee: DeuteRx, LLC
    Inventor: Vincent Jacques
  • HISTONE DEACETYLASE INHIBITORS
    Publication number: 20180370987
    Abstract: This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
    Type: Application
    Filed: July 26, 2018
    Publication date: December 27, 2018
    Inventors: Vincent Jacques, James R. Rusche, Norton P. Peet, Jasbir Singh
  • HDAC INHIBITORS
    Publication number: 20180362472
    Abstract: Disclosed herein are compounds of formula (I), and methods of inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3) using compounds of formula (I).
    Type: Application
    Filed: June 15, 2018
    Publication date: December 20, 2018
    Inventors: Vincent Jacques, James R. Rusche
  • HISTONE DEACETYLASE INHIBITORS
    Publication number: 20180327423
    Abstract: This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
    Type: Application
    Filed: July 26, 2018
    Publication date: November 15, 2018
    Inventors: Vincent Jacques, James R. Rusche, Norton P. Peet, Jasbir Singh
  • Histone deacetylase inhibitors
    Patent number: 10059723
    Abstract: This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: August 28, 2018
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Vincent Jacques, James R. Rusche, Norton P. Peet, Jasbir Singh